Adoptive Transfer of MART1/Melan-A CTL for Malignant Melanoma

DETAILED OUTLINE: This is an early phase pilot/feasibility trial. Study subjects will be sequentially accrued to three cohorts. Cohorts 1 and 2 will evaluate the safety and feasibility of infusing two different doses of CTL. * Participants in all cohorts will undergo two CTL infusions 5 weeks apart. * Procedures performed during the trial will include physical examinations, laboratory tests, delayed hypersensitivity testing, and skin biopsies. * Between 5 and 8 days after the first CTL infusion, a biopsy or excision of a melanoma lesion may be performed. * Three leukapheresis procedures will be performed: two to collect peripheral blood for CTL production and one for research purposes at the end of the clinical trial. * Radiology tests (including CT scans) will be performed prior to infusion and about 4-5 weeks after the second CTL infusion.